New injection aims to protect HIV Patients' hearts
NCT ID NCT03207945
Summary
This study tested if a cholesterol-lowering injection called alirocumab could reduce heart disease risk in people living with HIV. It involved 118 adults aged 40+ with well-controlled HIV and either existing heart disease or significant risk factors. Participants received either the drug or a placebo for a year to see if it reduced artery inflammation and improved blood vessel function.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
San Francisco General Hospital
San Francisco, California, 94110, United States
Conditions
Explore the condition pages connected to this study.